Considering the high safety of TR in clinic, our study provides a potentially new and practical pharmacological approach for treating NLRP3‐driven diseases, including CAPS, type 2 diabetes, and gout. The gene discussed is NLRP3; the disease is cryopyrin-associated periodic syndrome.